Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: a retrospective, multicenter study

about

New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer.

P2860

Q41283854-ED66C4D4-60BD-49F2-8B05-8D25D5CA0062

P2860

Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: a retrospective, multicenter study

Item

http://www.wikidata.org/entity/Q35841620

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Bevacizumab for the treatment ...... trospective, multicenter study

@ast

Bevacizumab for the treatment ...... trospective, multicenter study

@en

type

Item

label

Bevacizumab for the treatment ...... trospective, multicenter study

@ast

Bevacizumab for the treatment ...... trospective, multicenter study

@en

prefLabel

Bevacizumab for the treatment ...... trospective, multicenter study

@ast

Bevacizumab for the treatment ...... trospective, multicenter study

@en

P1476

Bevacizumab for the treatment ...... trospective, multicenter study

@en

P2093

Bárbara Parente

http://www.w3.org/2001/XMLSchema#string

Encarnação Teixeira

http://www.w3.org/2001/XMLSchema#string

Fernanda Estevinho

http://www.w3.org/2001/XMLSchema#string

Henrique Queiroga

http://www.w3.org/2001/XMLSchema#string

Isabel Azevedo

http://www.w3.org/2001/XMLSchema#string

Marta Soares

http://www.w3.org/2001/XMLSchema#string

Renato Sotto-Mayor

http://www.w3.org/2001/XMLSchema#string

Ulisses Brito

http://www.w3.org/2001/XMLSchema#string

P2860

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Bevacizumab in non small cell lung cancer.

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.

Isolation of a tumor factor responsible for angiogenesis.

[Epidemiological study of lung cancer in Portugal (2000/2002)].

P304

91-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S29672

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

A Araújo

P577

2012-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22457603

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

Portugal

multicenter trial

P932

3308635

http://www.w3.org/2001/XMLSchema#string

Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: a retrospective, multicenter study

about

P2860

P2860

Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: a retrospective, multicenter study

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932